Transaction
Anara Impact Capital, Global Innovation Fund, and Africa Health Ventures invest USD 1.45 million in Reme-D
- Announced
- 24 July 2026
- Target
- Reme-D, Inc.
- Value
- $1.5m
- Asset class
- Venture Capital
- Type
- Investment
- Instrument
- Ordinary Shares (Equity)
- Lead investors
- Anara Impact Capital
- Investors
- Anara Impact Capital, Africa Health Ventures, Undisclosed Investors, Global Innovation Fund
- Sector
- Healthcare / Medical Supplies, Biotechnology
- Markets
- Egypt, Kenya, Sudan
About the target
Reme-D, Inc. is an Egypt-based molecular-diagnostics manufacturer that develops diagnostic kits for infectious, genetic and other diseases. The company manufactures molecular tests designed for use in settings with limited cold-chain and laboratory infrastructure, including tests for tuberculosis, human immunodeficiency virus, hepatitis and human papillomavirus. Reme-D sells to public and private laboratories, hospitals and research institutions. Its website lists nucleic-acid extraction, diagnostic and research-use tools, while recent funding coverage reports that it has commercialised 30 products and supplied more than 550,000 tests in Egypt, Kenya and Sudan.
Sources
- disruptafrica.com
- Partner Researchers